Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. (symbol: VTGN) is a pioneering biotechnology firm committed to improving the lives of patients with central nervous system (CNS) disorders. The company leverages its advanced stem cell technology platform, which is based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed human cells. This innovative platform enables the creation of novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue, and cell therapy, providing clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
At the clinical stage, Vistagen is actively involved in developing and commercializing a robust pipeline consisting of six product candidates. Five of these candidates are clinical-stage investigational agents known as pherines, which represent a new class of drugs. Notable products within their portfolio include:
- PH94B: A novel neuroactive nasal spray designed to treat social anxiety disorder.
- PH10: An odorless, fast-acting synthetic neurosteroid aimed at addressing major depressive disorder (MDD).
- AV-101: An oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR), which is being developed to treat MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.
Vistagen's innovative approach and dedication to CNS disorders position it as a significant player in the biotechnology sector. The company is continually making strides in its research and clinical trials, striving to bring groundbreaking therapies to market. Investors and stakeholders can look forward to Vistagen's ongoing developments and potential future successes as it targets unmet medical needs with its cutting-edge technologies and therapeutic candidates.
Vistagen (Nasdaq: VTGN) reported its fiscal year 2024 financial results, showcasing significant progress in its clinical programs. The company highlighted positive results from the PALISADE-2 Phase 3 trial of fasedienol for social anxiety disorder (SAD), with PALISADE-3 initiated and PALISADE-4 set to start in 2H 2024. Additionally, itruvone for major depressive disorder (MDD) and PH80 for menopausal hot flashes showed positive Phase 1 and Phase 2A data, respectively. Financially, Vistagen's R&D expenses decreased to $20.0 million from $44.4 million, and G&A expenses slightly fell to $14.1 million from $14.7 million. The net loss was significantly reduced to $29.4 million compared to $59.2 million in the previous year. Cash and cash equivalents stood at $119.2 million as of March 31, 2024.
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company focusing on psychiatric and neurological disorders, will report its fiscal year 2024 financial results on June 11, 2024.
The announcement will be made through a conference call and webcast at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). During the call, Vistagen will provide a detailed update on its corporate activities and financial performance for the fiscal year ending March 31, 2024.
Participants can join the call using the toll-free number 1-877-407-9716 in the US, or 1-201-493-6779 internationally, with the Conference ID: 13746589. A replay will be available shortly after the call ends.
Vistagen, a late clinical-stage biopharmaceutical company focused on innovative therapies for psychiatric and neurological disorders, announced its participation in the Jefferies Global Healthcare Conference on June 5-6, 2024, in New York City.
CEO Shawn Singh will present a fireside chat on June 6 at 11:00 a.m. EST, with a webcast available on Vistagen's website. Interested investors can arrange one-on-one meetings through their Jefferies representative.
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, announced it will present posters at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference from May 28-31, 2024, in Miami Beach, Florida.
The presentations will focus on fasedienol (PH94B) for social anxiety disorder (SAD) and itruvone (PH10) for major depressive disorder (MDD). The fasedienol poster, titled 'Results from the PALISADE-2 Phase 3 Trial,' will be presented on May 29, 2024, at 11:15 a.m. ET. The itruvone poster, titled 'Brain and Peripheral Tissue Distribution of Intranasal Radiolabeled Itruvone (PH10) in Laboratory Rats,' will also be presented on May 29, 2024, at 11:15 a.m. ET.
Both posters will be available on Vistagen's website from June 3, 2024.
Vistagen (Nasdaq: VTGN) will be presenting at the 2024 RBC Capital Markets Global Healthcare Conference in New York City. CEO Shawn Singh will participate in a fireside chat on May 15. Investors can arrange one-on-one meetings through their RBC representative.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
What does Vistagen Therapeutics, Inc. specialize in?
What is the company's main technological focus?
What are pherines?
Can you name some of Vistagen Therapeutics' key products?
What is PH94B used for?
What is PH10?
What conditions is AV-101 aimed at treating?
How does Vistagen's stem cell technology benefit drug development?
Is Vistagen Therapeutics currently in the clinical stage?
Where can I find the latest news about Vistagen Therapeutics, Inc.?
